PYXS Pyxis Oncology Inc

Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, and members of the management team will present at the following upcoming investor conferences:

H.C. Wainwright Global Investment Conference

Date: Tuesday, May 24, 2022

Time: 7:00 a.m. ET

Format: Pre-recorded presentation available on-demand and virtual 1:1 meetings

Jefferies Healthcare Conference

Date: Wednesday, June 8, 2022

Time: 2:00 p.m. ET

Format: Live presentation and 1:1 meetings in New York, NY

Webcasts of these presentations can be accessed on the Investors section of the Pyxis Oncology website at ir.pyxisoncology.com. A replay of the presentations will be available on the Company’s website for up to 90 days following each event.

About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a multi-asset multi-modality company focused on defeating difficult to treat cancers and improve patient lives. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis Oncology visit www.pyxisoncology.com.

Pyxis Oncology Contact:Courtney DuganVice President, Head of Investor Relations & Corporate Communications(617) 500-8872ir@pyxisoncology.com